<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132922</url>
  </required_header>
  <id_info>
    <org_study_id>ADP-0044-001</org_study_id>
    <nct_id>NCT03132922</nct_id>
  </id_info>
  <brief_title>MAGE-A4ᶜ¹º³²T for Multi-Tumor</brief_title>
  <official_title>Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adaptimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adaptimmune</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in
      subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma,
      head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or
      myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study
      will take a subject's T cells and give them a T cell receptor protein that recognizes and
      attacks the tumors. This study has a substudy component that will investigate the safety and
      tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">September 2035</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events (AE), including serious adverse events (SAEs).</measure>
    <time_frame>3.5 years</time_frame>
    <description>Determine if treatment with autologous genetically modified T cells (MAGE-A4ᶜ¹º³²T) is safe and tolerable through laboratory assessments including chemistry, hematology and coagulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determining dose limiting toxicities (DLT) and optimally tolerated dose range</measure>
    <time_frame>3.5 years</time_frame>
    <description>Evaluate DLTs and toxicity assessment using NCI CTCAE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of persistence of genetically modified T cells.</measure>
    <time_frame>3.5 years</time_frame>
    <description>Evaluation of persistence of genetically modified T cells in the periphery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of RCL in genetically modified T cells.</measure>
    <time_frame>3.5 years</time_frame>
    <description>Evaluation of RCL in subject PBMCs using PCR-based assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR).</measure>
    <time_frame>3.5 years</time_frame>
    <description>Evaluation of the efficacy of the treatment by assessment of the Overall Response Rate according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interval between the date of first T cell infusion dose and first documented evidence of CR or PR.</measure>
    <time_frame>3.5 years</time_frame>
    <description>Evaluation of the efficacy of the treatment by assessment of time to first response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause.</measure>
    <time_frame>3.5 years</time_frame>
    <description>Evaluation of the efficacy of the treatment by assessment of duration of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interval between the date of first documented evidence of stable disease (SD) until first documented disease progression or death due to any cause.</measure>
    <time_frame>3.5 years</time_frame>
    <description>Evaluation of the efficacy of the treatment by assessment of duration of stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interval between the date of first T cell infusion and the earliest date of disease, progression or death due to any cause</measure>
    <time_frame>3.5 years</time_frame>
    <description>Evaluation of the efficacy of the treatment by assessment of progression-free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interval between the date of first T cell infusion and date of death due to any cause.</measure>
    <time_frame>3.5 years</time_frame>
    <description>Evaluation of the efficacy of the treatment by assessment of overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)</measure>
    <time_frame>15 years post last treatment (infusion)</time_frame>
    <description>New occurrence of any malignancy
New occurrence or exacerbation of a pre-existing neurologic disorder
New occurrence or exacerbation of a prior rheumatologic or other autoimmune disorder
New occurrence of a hematologic disorder
New occurrence of any opportunistic and/or serious infections
New occurrence of any unanticipated illness and/or hospitalization deemed related to gene modified cell therapy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>MAGE-A4c1032T cell trafficking in tumor lesion(s).</measure>
    <time_frame>3.5 years</time_frame>
    <description>Evaluation of post-infusion T-cell trafficking in irradiated vs non-irradiation lesions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Urinary Bladder Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Synovial Sarcoma</condition>
  <condition>Myxoid Round Cell Liposarcoma</condition>
  <condition>Gastroesophageal Junction</condition>
  <arm_group>
    <arm_group_label>Autologous genetically modified MAGE-A4ᶜ¹º³²T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiation Sub-Study: Autologous genetically modified MAGE-A4c1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Autologous genetically modified MAGE-A4ᶜ¹º³²T cells</intervention_name>
    <description>Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1</description>
    <arm_group_label>Autologous genetically modified MAGE-A4ᶜ¹º³²T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation</intervention_name>
    <description>Up to 10 subjects will be considered for Radiation sub-study. Radiation with an intensity of 1.4Gy for 5 days before infusion of MAGE-A4c1032T cells</description>
    <arm_group_label>Radiation Sub-Study: Autologous genetically modified MAGE-A4c1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is ≥18 years of age at the time of signing the study informed consent.

          2. Subject has histologically confirmed diagnosis of any one of the indicated tumor types

          3. Subject is HLA-A*02 positive. (This determination will be made under screening
             protocol ADP-0000-001).

          4. Subject's tumor shows expression of the MAGE-A4 RNA or protein. (This determination
             will be made under screening protocol ADP-0000-001).

          5. Adequate organ function as indicated in the study protocol

          6. Subject has measurable disease according to RECIST v1.1 criteria prior to
             lymphodepletion

          7. Subject meets disease-specific requirements per protocol

        7. Subject has anticipated life expectancy &gt; 6 months prior to leukapheresis and &gt;3 months
        prior to lymphodepletion.

        Exclusion Criteria:

          1. Subject does not express appropriate HLA-A genotype

          2. Subject is receiving excluded therapy/treatment per protocol

          3. Subject has symptomatic CNS metastases.

          4. Subject has any other active malignancy besides the tumor under study within 3 years
             prior to Screening. Subject has uncontrolled intercurrent illness.

          5. Subject has active infection with HIV, HBV, HCV or HTLV

          6. Subject is pregnant or breastfeeding.

        Additional Exclusion Criteria for the Radiation Substudy:

          -  Subject does not meet eligibility criteria for the main study (ADP-0044-001).

          -  Subject does not have at least one target lesion amenable to radiation.

          -  Certain radiation therapy within 6 months of clinical trial are an exclusion.

          -  Metastatic disease impinging on the spinal cord or threatening spinal cord
             compression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Hong, MD</last_name>
    <phone>713-563-5844</phone>
    <email>dshong@madanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Liendo</last_name>
      <phone>305-243-0864</phone>
      <email>mliendo@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Munevar</last_name>
    </contact_backup>
    <investigator>
      <last_name>Brian Slomovitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Taddeo</last_name>
      <phone>817-745-1346</phone>
      <email>Matt.Taddeo@moffitt.org)</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Soto</last_name>
      <phone>813-745-4608</phone>
      <email>Rachel.Soto@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michaele Druta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Landeau</last_name>
      <phone>314-747-7997</phone>
      <email>landeaum@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cheryl Callahan</last_name>
    </contact_backup>
    <investigator>
      <last_name>Brian Van Tine, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Whitworth, BSN</last_name>
      <phone>716-845-8409</phone>
      <email>Amy.Whitworth@roswellpark.org</email>
    </contact>
    <contact_backup>
      <last_name>Dawn DePaolo</last_name>
    </contact_backup>
    <investigator>
      <last_name>Kunle Odunsi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawna Savage, RN, BSN</last_name>
      <phone>919-668-1462</phone>
      <email>shawna.savage@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey M Clarke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Schweitzer</last_name>
      <phone>614-685-5414</phone>
      <email>catherine.schweitzer@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>David Liebner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Olszanski, MD, RPh</last_name>
      <email>Anthony.Olszanski@FCCC.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Olszanski, MD, RPh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology - Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Walker</last_name>
      <phone>615-339-4214</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danxia Ke</last_name>
      <phone>713-792-4384</phone>
      <email>dke@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>David Hong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Sacher, MD</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>5485</phone_ext>
      <email>TIP@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Adrian Sacher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 25, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Therapy</keyword>
  <keyword>T Cell Therapy</keyword>
  <keyword>SPEAR T Cell</keyword>
  <keyword>MAGE-A4</keyword>
  <keyword>Immuno-oncology</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Urothelial Cancer</keyword>
  <keyword>Previously Treated</keyword>
  <keyword>T Cell Receptor</keyword>
  <keyword>Squamous, adenosquamous, adenocarcinoma or large cell NSCLC</keyword>
  <keyword>Squamous or adenocarcinoma esophageal cancer</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Bladder</keyword>
  <keyword>Ovarian</keyword>
  <keyword>Radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Sarcoma, Synovial</mesh_term>
    <mesh_term>Liposarcoma, Myxoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

